Clinical trials bring life extending and curative new treatments to cancer patients. Clinical drug trials play a vital role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients.  Use this tool to find clinical trials.

There are currently over 140 Phase III drug trials and more than 650 Phase I/II trials related to prostate cancer treatment in progress in the United States alone. Those that are approved will join the nine new drugs that have been approved for men with advanced metastatic disease since 2010 and further improve outcomes for patients:

The resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. If you are considering a clinical trial, speak to your doctor about the potential benefits of participating in a trial so you can make an informed decision that is best for you.


Frequently Asked Questions (FAQs)

To view our FAQs about Clinical Trials, please visit here.


Prostate Cancer Clinical Trials Consortium

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan Kettering Cancer Center. The PCCTC is currently composed of 11 participating clinical research sites and 32 affiliated clinical research sites.

Visit the PCCTC site for trial information: www.pcctc.org


Open Trials

For a complete list of open trials in the United States, please visit:
clinicaltrials.go



Halo Diagnostics

Phase II Study to Evaluate Outpatient Magnetic Resonance Image-guided Laser Focal Therapy for Prostate Cancer, a 20-year Survival Study

HALO Diagnostics (formerly Desert Medical Imaging) is conducting this clinical trial to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate oncologic control over 20 years. The investigators are evaluating the efficacy of a novel, FDA-approved thermal therapy and feedback system (Visualase® Thermal Therapy System) for the treatment of prostate lesions confirmed by biopsy and visible through MRI-based imaging. An MRI uses large magnets to produce pictures of areas/organs inside the body. The laser uses light to heat a target area to try to destroy cancerous cells. The laser system that will be used is called the Visualase® Thermal Therapy System. This system has been used for the treatment of brain, bone (spine), thyroid, and liver cancers. This study is the first time this laser system has been studied for use in the treatment of prostate cancer with a trans-rectal approach. MR-guided biopsies and laser applicator placement will be performed using the Invivo DynaTRIM trans-rectal biopsy guidance system. This system is cleared (approved) by the U.S. Food and Drug Administration (FDA) for such uses. This study has a target recruitment of 1000 subjects.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT02243033?cond=02243033&draw=2&rank=1



Tmunity

CART-PSMA-TGFβRDN-02 Study

Tmunity Therapeutics is now enrolling men in a Phase 1 single-arm study, who have metastatic castration‐resistant prostate cancer (mCRPC) investigating a new Chimeric Antigen Receptor T (CART) cell treatment, which uses the body’s own immune system (a type of white blood cells called “T” cells) to attempt to attack prostate cancer cells.

Eligible participants will undergo leukapheresis, a process that collects the participant’s own white blood cells. These cells are then genetically modified in a lab so the cells will be able to target the participant’s prostate cancer tumor cells once infused back into the participant. These genetically modified cells are called CART-PSMA-TGFβDN cells.

To be eligible for this trial, patients with metastatic castration-resistant prostate cancer must have received at least 2 prior lines of therapy for prostate cancer. Additional eligibility criteria will apply.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT04227275


PCF

The MAGNITUDE Study

WHY IS THIS CLINICAL RESEARCH STUDY BEING DONE?
The MAGNITUDE Study is a Phase 3 randomized, placebo­-controlled, double-­blind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.

AM I ELIGIBLE?
You may be eligible to participate in this study if you:

  • Are a male, age 18 or older
    Have a diagnosis of metastatic prostate cancer (which means that cancer has spread to other parts in your body such as bones, liver or lung)
  • Are willing to provide a blood sample and tumor tissue sample as part of the study

Before you participate in this study, a detailed description of the study, as well as possible risks and benefits, will be provided in writing in an “informed consent document” and discussed with you. You will be asked to review and sign the informed consent document prior to participating. Your medical history will be reviewed, and you will be given a study­required medical exam and have study­-required laboratory tests such as blood draws.

STUDY DESIGN
The purpose of the study is to compare a combination of the investigational medicine to standard treatment versus a combination of placebo and standard treatment for the treatment of patients with metastatic prostate cancer. A placebo is an inactive treatment, sometimes referred to as a “sugar pill,” that will be provided as capsules and will match the investigational medicine in size, weight, color, shape, and taste

Once enrolled in the study, feel free to discuss your investigational medication with the study doctor or research staff at any time during the study. Information collected during a clinical research study may or may not ultimately lead to the investigational medicine(s) being approved by regulatory health authorities.

Your participation in the study is voluntary and you can leave the study at any time. Compensation for time and travel may be available.

To learn more about this study and to find out if you may be eligible and if the study is being conducted at a site near you, please visit:
https://clinicaltrials.gov/ct2/show/NCT03748641?term=NCT03748641&rank=1


PCF

The GALAHAD Study

A clinical research study is now enrolling men who have metastatic castration‐resistant prostate cancer and DNA‐repair anomalies. Janssen Research & Development is seeking men in the US to participate in a clinical trial of an oral investigational medication for prostate cancer. All participants will receive daily investigational medication.

To learn more about this study and to find out if you may be eligible, please visit: https://www.clinicaltrials.gov/ct2/show/NCT02854436?term=NCT02854436&rank=1

ClinicalTrials.gov Identifier: NCT02854436

Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.


UCLA Jonsson logo

Phase 3 randomized trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

A clinical research study is now enrolling men with recurrent prostate cancer after radical prostatectomy who have a PSA of at least 0.1 ng/mL and are planned to undergo salvage radiotherapy.
The purpose of this research study is to assess the impact of 68Ga-PSMA-11 PET/CT, an experimental imaging scan for prostate cancer, on the success of salvage prostate radiotherapy.
Eligible participants will be randomized to undergo a specialized scan called 68Ga-PSMA-11 PET/CT, or not, prior to their planned salvage radiotherapy. The scan will require approximately 3 hours including traveling time.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03582774

ClinicalTrials.gov Identifier: NCT03582774


Merck logo

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Merck is conducting this clinical trial to find out if the investigational medication pembrolizumab in combination with abiraterone and prednisone is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCPRC). Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This trial is currently enrolling patients with mCRPC who have not received chemotherapy for mCRPC and have either not had prior second generation hormonal manipulation for mCRPC, or have previously been treated with enzalutamide for mCRPC and failed treatment or has become intolerant of the drug. Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT02861573

ClinicalTrials.gov Identifier: NCT02861573


Merck logo

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Merck is conducting this clinical trial to find out if the investigational medication pembrolizumab in combination with enzalutamide is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCPRC) compared to enzalutamide alone. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. To be eligible for this trial, patients with mCRPC must not have received chemotherapy for mCRPC and have either not received treatment with abiraterone acetate or have received treatment with abiraterone acetate but did not respond or are no longer responding to it. Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03834493

ClinicalTrials.gov Identifier: NCT03834493


Merck logo

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Merck is conducting this clinical trial to find out if the investigational medication pembrolizumab in combination with docetaxel and prednisone is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCPRC) compared to docetaxel and prednisone alone. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. To be eligible for this trial, patients with mCRPC must not have received chemotherapy for mCRPC and have received prior treatment with either abiraterone acetate or enzalutamide (but not both). Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03834506

ClinicalTrials.gov Identifier: NCT03834506


Merck logo

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Merck is conducting this clinical trial to find out if the combination of two investigational medications, pembrolizumab and olaparib, is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCRPC) compared to the standard of care. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. Olaparib is a targeted therapy called a PARP inhibitor that may help limit a cancer cell’s ability to repair itself and leads to the death of cancer cells. To be eligible for this trial, patients with mCRPC must have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy. Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03834519

ClinicalTrials.gov Identifier: NCT03834519


Constellation_Pharm

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

This is a two-arm, open label phase 1b/2 trial with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in men with metastatic castration resistant prostate cancer. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone.

Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03480646?term=NCT03480646&rank=1

ClinicalTrials.gov Identifier: NCT03480646


BeiGene

Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Deficiency

This is a global, Phase 2, open-label study of pamiparib in approximately 100 patients with with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). Subjects in Cohort 1 will include 50 mCRPC patients with CTC-HRD-positive, measurable metastatic disease (soft tissue with/without bone lesions), and positive BRCA1/2 mutation or negative/unknown BRCA1/2 mutation. Cohort 2 will include 30 mCRPC CTC-HRD positive patients with bone metastasis only and positive or negative/unknown BRCA1/2. Cohort 3 and 4 will include 20 mCRPC CTC-HRD negative/unknown patients with BRCA1/2 positive mutations, metastatic disease (measurable soft tissue with/without bone), and bone only. Subjects will undergo PSA level assessments approximately every 4 weeks as well as tumor assessments every 8 weeks, or as clinically indicated. Administration of pamiparib will continue until disease progression, unacceptable toxicity, death or another discontinuation criterion is met.

To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT03712930

ClinicalTrials.gov Identifier: NCT03712930


Additional open trials can be found by going to:

PCF

PCF

PCF


Literature:

PCFCancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials

Tomasz M. Beer, MD
Larry Axmaker, Ed.D.

Written from both a patient and clinician perspective by Larry Axmaker, Ed.D., and Tomasz M. Beer, MD, a PCF-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy. Order Here »

Learn More

  • Financial Resources

    Navigating a prostate cancer diagnosis can be difficult on multiple fronts. We have collected a list of resources to help with the costs of co-payments,...

  • For Some Advanced Cancers, What...

    Janet Farrar Worthington

    We may have turned the corner.  We’re not there yet, but wow, are we hopeful!  At the Prostate Cancer Foundation, our goal has always been...